Abstract:SummaryThe purpose of the present study was to study the characteristics of epidemic growth factor receptor (EGFR) gene distribution in patients with non-small cell lung cancer (NSCLC), and to detect the mutation rate of EGFR gene by Sanger sequencing and amplification refractory mutation system (ARMS)-PCR. Paraffin-embedded sections of NSCLC tissues from 399 NSCLC patients diagnosed in Renmin Hospital of Wuhan University were collected, 103 of them were detected for exons 18–21 mutation of EGFR by Sanger sequencing method, 296 cases were detected for exons 18–21 mutation by ARMS-PCR method. DNA extraction of both groups was performed with Qiagen QLAamp DNA FFPE Tissue KIT. Comparisons of detection rates between the two methods were conducted by row X list chi-square test. The total mutation rate of EGFR gene detected by Sanger sequencing was 21.4%, exons 18–21 and combined mutation rates were 1.0%, 9.7%, 1.0%, 7.8% and 2.0%, respectively. And the proportions were 4.7%, 45.2%, 4.7%, 36.3% and 9.4% respectively. The total mutation rate detected by ARMS-PCR was 51.4%, exons 18–21 and combined mutation rates were 2.7%, 27%, 1.7%, 18.2% and 1.7%, respectively. The proportions were 5.3%, 52.6%, 3.3%, 35.5% and 3.3% respectively. Further analysis of mutation rate showed that there was significant difference between the two methods in detecting total mutation of EGFR gene (P<0.001). There were significant differences in mutation detection rates of exons 19 and 21 (P<0.001, P<0.05), but there were no significant differences in other exons. And there was no significant difference in mutation detection rates between the two methods. The mutation rate of EGFR gene in NSCLC patients was 50%. And exon 19 deletion was the most common mutation type, followed by exon 21 mutation. Compared with Sanger sequencing method, ARMS method is more sensitive with significant advantages in detecting exon 19 deletions and exon 21 mutations, which can be widely used in clinical detection of EGFR gene mutations. The results of this study will further guide patients with advanced NSCLC to select TKI targeted drugs, and provide clinical diagnostic basis for targeted therapy of NSCLC patients.

Supplementary Data from Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Detection of EGFR gene mutations with mutation-speciifc immunohistochemistry in non-small cell lung cancer

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data

The Use of Mutation-Specific Antibodies in Predicting the Effect of EGFR-TKIs in Patients with Non-Small-cell Lung Cancer

Diagnostic Value Of Mutation-Specific Antibodies For Immunohistochemical Detection Of Epidermal Growth Factor Receptor Mutations In Non-Small Cell Lung Cancer: A Meta-Analysis

Immunohistochemical Detection of Mutations in the Epidermal Growth Factor Receptor Gene in Lung Adenocarcinomas Using Mutation-Specific Antibodies.

Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients

Immunohistochemistry Using Epidermal Growth Factor Receptor Mutation-Specific Antibodies of Dele746-A750 and L858R in Lung Adenocarcinomas

[The Detection by Denaturing High Performance Liquid Chromatography of Epidermal Growth Factor Receptor Mutation in Tissue and Peripheral Blood from Patients with Advanced Non-Small Cell Lung Cancer].

Supplementary Data from Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC

EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer

Supplementary Figure 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Data from A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay

Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Abstract 2742: Cross-platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Plasma of Patients with Non-Small Cell Lung Carcinoma